Clinical Trials Logo

Urinary Bladder Diseases clinical trials

View clinical trials related to Urinary Bladder Diseases.

Filter by:

NCT ID: NCT06395701 Recruiting - Bladder Cancer Clinical Trials

Trimodality Treatment in Bladder Cancer

Start date: April 1, 2014
Phase:
Study type: Observational

Bladder cancer is a malignant disease that affects a large number of people worldwide. An increase in the incidence of this type of cancer has been observed in recent decades, leading to a growing interest in understanding its risk factors, clinical evolution, and possible treatment approaches. This retrospective study aims to retrospectively analyze a cohort of patients diagnosed with muscle-invasive bladder cancer, in whom, after presentation at multidisciplinary oncology committees, the goal of curing the oncological disease while preserving the bladder is considered. Trimodal therapy (TMT) is the most studied bladder preservation strategy, with oncological outcomes superior to those of isolated therapies (or monotherapies) such as transurethral resection of the bladder tumor (TURBT), radiotherapy, or chemotherapy. TMT consists of complete and maximal TURBT of the bladder tumor, followed by definitive radiotherapy combined with a radiosensitizing agent. Objectives The main objective is to retrospectively analyze the effectiveness and safety of the trimodal approach in our setting. Collecting and analyzing data from patients treated in our service will provide valuable insight into clinical outcomes and treatment tolerability in this context. Materials and Methods - Study Design A retrospective study will be conducted using data from medical records of patients diagnosed with bladder cancer from 2014 to 2022 and treated with radiotherapy in our Radiation Oncology Service. Demographic data, medical history, risk factors, clinical characteristics, treatments received, and clinical outcomes will be collected. - Study Population The study population will include all patients with confirmed diagnoses of non-metastatic muscle-invasive bladder cancer.

NCT ID: NCT06364865 Enrolling by invitation - Acute Cholecystitis Clinical Trials

AE05ML Device for ML Hem-o-lok Polymer Clip Delivery in Laparoscopic Surgical Procedures Observational Registery Study

AE05ML
Start date: June 7, 2024
Phase:
Study type: Observational [Patient Registry]

This clinical registry study aims to evaluate the safety and effectiveness of the AE05ML device for ligating vessels and tissue structures during laparoscopic surgery using Hem-o-lok® Medium Large (ML) polymer clips. The primary objective is to assess the device's safety and performance, with secondary objectives focusing on device performance characteristics and operator feedback.

NCT ID: NCT06337942 Recruiting - Bladder Cancer Clinical Trials

Deceased Donor Bladder or Combined Kidney-bladder Transplantation: a Phase 0 First-in-human Study

Start date: July 1, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to demonstrate the feasibility of bladder transplantation in patients with terminal bladder diseases who would benefit from a new bladder or a combined kidney and bladder transplant. The main questions it aims to answer are: - Is human bladder transplantation feasible and safe? - How will the new bladder function in terms of storage and emptying? Participants will undergo a bladder-only or combined kidney and bladder transplantation. They will then be followed for two years to evaluate the efficacy, safety, and functionality of the bladder transplant.

NCT ID: NCT06237920 Recruiting - Neoplasms Clinical Trials

Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab

TURANDORELA
Start date: February 19, 2024
Phase: Phase 2
Study type: Interventional

This is a non-blinded phase 2 trial in Stage II-IIIa urothelial cancer randomizing pre-operative nivolumab with or without relatlimab to assess whether bladder preservation after dual immunotherapy would be a viable treatment option for patients responding to treatment

NCT ID: NCT06185218 Not yet recruiting - Bladder Disease Clinical Trials

Different Injection Site Maps & Intravesical Botulinum Toxin

Start date: April 2024
Phase: N/A
Study type: Interventional

Botulinum toxin injection into the bladder is used in current practice in urological diseases such as overactive bladder or interstitial cystitis. As far as is known, botulinum toxin injection sites have not been clearly defined. In this study, investigators are planning to compare botulinum toxin effectiveness with different injection site maps.

NCT ID: NCT06167356 Recruiting - Bladder Cancer Clinical Trials

Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK.

Start date: November 27, 2013
Phase:
Study type: Observational

A database has been created and will be used in which data will be collected in electronic format relating to adult patients who underwent one of the following endoscopic resection surgeries: TURBK, MAPPING, TURBK SECOND LOOK, BLADDER BIOPSIES.

NCT ID: NCT06083558 Recruiting - Postoperative Pain Clinical Trials

Pain and Nausea After Gallbladder Surgery

Start date: January 1, 2016
Phase:
Study type: Observational [Patient Registry]

The study is primarily an exploratory study of quality registry data for a swedish national cohort of patients who have undergone gallbladder surgery or ERCP, with the aim of investigating the occurrence of pain and PONV (Postoperative Nausea and Vomiting) after gallbladder surgery. Furthermore, the investigators will explorer if there are factors related to the patient or the surgical procedure that are associated with a higher risk of PONV or pain.

NCT ID: NCT05979233 Recruiting - Clinical trials for Gall Bladder Disease

One Session Vs Staged Management of Calcular Obstructive Jaundice

Start date: August 5, 2023
Phase: N/A
Study type: Interventional

to compare the outcomes between doing ERCP and laparoscopic cholecystectomy in one session Vs staged management

NCT ID: NCT05941884 Not yet recruiting - Clinical trials for Schistosoma Haematobium

Possible Diagnostic Protein Markers in Schistosoma Related Bladder Diseases.

Start date: October 1, 2023
Phase:
Study type: Observational

Schistosomiasis is the second most common parasitic infection affecting humans, endemic in the Middle East, especially Egypt (1), and in 42 African countries (2). There are 5 main species infecting humans: S. mansoni, S. haematobium, S. japonicum, S. intercalatum, and S. mekongi. S. haematobium is responsible for chronic urogenital infections that may cause serious complications (3). Urinary schistosomiasis is mostly borne in rural and agricultural communities, according to WHO (4)

NCT ID: NCT05927870 Not yet recruiting - Clinical trials for Gall Bladder Disease

Ultrasound Guided Percutaneous Cholecystostomy.

Start date: August 1, 2023
Phase: N/A
Study type: Interventional

Surgical cholecystostomy has proven value in the management of both inflammatory and obstructive biliary tract disease